SuperworthExelixis EPS EXEL
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jul 3, 2026
- $3.18
- Latest quarter, Q2 FY26
- $0.82
- +26% on a year earlier
- Fiscal year 2025
- $2.77
- +56% on the year before
Exelixis' earnings per share was $3.18 over the twelve months to Jul 3, 2026, up 53% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.82, up 26% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 51% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.77 | +56% |
| FY2024 | $1.77 | +177% |
| FY2023 | $0.64 | +12% |
| FY2022 | $0.57 | −20% |
| FY2021 | $0.71 | +103% |
| FY2020 | $0.35 | −66% |
| FY2019 | $1.02 | −54% |
| FY2018 | $2.21 | +351% |
| FY2017 | $0.49 | n/a |
| FY2012 | −$0.91 | −269% |
| FY2011 | $0.54 | n/a |
| FY2010 | −$0.85 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.82 | +26% | $3.18 | |
| Q1 FY26 | $0.79 | +44% | $3.01 | |
| Q4 FY25 | $0.88 | +83% | $2.77 | |
| Q3 FY25 | $0.69 | +73% | $2.37 | |
| Q2 FY25 | $0.65 | −16% | $2.08 | |
| Q1 FY25 | $0.55 | +358% | $2.20 | |
| Q4 FY24 | $0.48 | +78% | $1.77 | |
| Q3 FY24 | $0.40 | n/a | $1.56 | |
| Q2 FY24 | $0.77 | +208% | $1.16 | |
| Q1 FY24 | $0.12 | +0% | $0.64 | |
| Q4 FY23 | $0.27 | n/a | $0.64 | |
| Q3 FY23 | $0.00 | −100% | $0.28 |
Against its peers
Companies in Biotechnology nearest Exelixis' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| EXELExelixis | $3.18 | +53% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| RGENRepligen | $0.73 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| ONCBeOne Medicines | $0.43 | |
| REGNRegeneron Pharmaceuticals | $40.44 | +2% a year |
| Peer median | $6.38 |
Where Exelixis ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Exelixis
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.